Edgewise Therapeutics, Inc. (EWTX) Stock Analysis & Investment Frameworks
Edgewise Therapeutics, Inc. (EWTX) stock analysis on Invetso. Review Edgewise Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Edgewise Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Edgewise Therapeutics, Inc. Key Financial Metrics
- Market Cap: $4.27B
- Revenue: $N/A
- ROE: -39.01%
- ROIC: -48.46%
- Dividend Yield: N/A
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Edgewise Therapeutics, Inc. Investment Frameworks
Invetso analyzes Edgewise Therapeutics, Inc. (EWTX) across the following frameworks:
- Edgewise Therapeutics, Inc. 10Y Growth Potential
- Edgewise Therapeutics, Inc. Scenario Analysis
- Edgewise Therapeutics, Inc. Risks & Opportunities
- Edgewise Therapeutics, Inc. Economic Moat
- Edgewise Therapeutics, Inc. Business Model
- Edgewise Therapeutics, Inc. Management
- Edgewise Therapeutics, Inc. SWOT Analysis
- Edgewise Therapeutics, Inc. Porter's 5 Forces
- Edgewise Therapeutics, Inc. PESTLE Analysis
- Edgewise Therapeutics, Inc. ESG Analysis